Study of Glaucoma Treatment With Food Additives
This study has been terminated.
(The trial was terminated due to investigator's decision)
Information provided by:
Future Products Management
First received: September 12, 2005
Last updated: March 10, 2009
Last verified: March 2009
The purpose of this study is to determine if certain food additives are effective in the treatment of glaucoma, improving and reversing the progress of the disease.
Drug: Vitamins, minerals and medical herbs
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
||Treatment of Glaucomatous Neuropathy With Food Additives
Primary Outcome Measures:
- Improvement in vision field (Protocol24) in a Humphrey's instrument. Scoring according to the Agis study
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2008 (Final data collection date for primary outcome measure)
Glaucomatous neuropathy is a condition that worsens with time causing atrophy of the optic nerve and narrowing of the visual field which may culminate in blindness. The treatment tested in the trial employs certain food additives intended to reverse this pathology.
|Ages Eligible for Study:
||40 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Stable open angle glaucoma - with equilibrated eye internal pressure
- Above the age of 50 years and have severe damage that does not progress to the vision field in the upper and lower half. Scoring of the vision field will be made according to the Agis study instructions.
- Eye diseases excluding past cataract operation
- Allergy to one of the components in the preparation
- Deterioration in the vision field in the last year
- Kidney diseases, gastrointestinal (G.I.) tract, liver diseases, coagulation problems and thyroid diseases
- Persons who take steroids
- Diabetics or unbalanced hyperglycemia
- Autoimmune diseases
- Hypertension (not responding to treatment)
- Psychiatric treatment with drugs, psychiatric pathologies
- Ability to take more than 3 pills per day regularly
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00196677
|Sheba Medical Center
|Tel Hashomer, Israel, 52621 |
Future Products Management
||Meir Gorban, MD
||Future Products Management
||Hani Levkovitch-Verbin, MD
||Sheba Medical Center
No publications provided
ClinicalTrials.gov processed this record on July 30, 2015
||Dr. Meir Gorban, Future Products Management
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 12, 2005
||March 10, 2009
||Israel: Israeli Health Ministry Pharmaceutical Administration